GlassScriptPhysician profile
Zemeng Luo
NPI 1659769073
$4,030.37
in general payments reported to CMS, 2019-2025
22 companies · $1,415 in 2025
The $1,415 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $812 · 2024: $1,803 · 2025: $1,415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,030.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,030.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $626.01 | 2023-2025 | Tavneos, Evenity, Krystexxa |
| Glaxosmithkline, LLC. | $617.38 | 2023-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Gilead Sciences, INC. | $346.92 | 2024-2025 | Yeztugo, Vemlidy |
| Bayer Healthcare Pharmaceuticals INC. | $319.66 | 2024-2025 | |
| Lilly USA, LLC | $280.49 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Agios Pharmaceuticals, INC. | $256.61 | 2024-2025 | Pyrukynd |
| Novo Nordisk INC | $175.24 | 2024-2025 | Wegovy |
| Stryker Corporation | $173.45 | 2024 | Omnicurve |
| Cequr Corporation | $148.28 | 2023 | Cequr Simplicity |
| Merck Sharp & Dohme LLC | $141.16 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Dynavax Technologies Corporation | $135.91 | 2024-2025 | Heplisav-B |
| Astrazeneca Pharmaceuticals LP | $135.86 | 2024-2025 | Breztri, Fasenra, Airsupra |
| Mallinckrodt Hospital Products INC. | $131.60 | 2023-2025 | Acthar |
| Horizon Therapeutics Plc | $124.30 | 2023 | Krystexxa |
| Calliditas Therapeutics US INC. | $121.43 | 2024-2025 | Tarpeyo |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.25 | 2024-2025 | Ofev, Jardiance |
| Dexcom, INC. | $49.15 | 2024-2025 | Dexcom G6 Transmitter |
| Scilex Pharmaceuticals INC. | $43.43 | 2024-2025 | |
| Sanofi Pasteur INC. | $41.37 | 2025 | |
| Pfizer INC. | $26.03 | 2023 | |
| Xeris Pharmaceuticals, INC. | $20.32 | 2023 | Gvoke Hypopen |
| Janssen Pharmaceuticals, INC | $19.52 | 2023 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zemeng Luo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.